Malaysia Chronic Pain Therapeutics Market Analysis

Malaysia Chronic Pain Therapeutics Market Analysis


$ 3999

The Malaysia Chronic Pain Therapeutics Market is anticipated to experience a growth from $119 Mn in 2022 to $192 Mn by 2030, with a CAGR of 6.1% during the forecast period of 2022-2030. Malaysia is witnessing market growth due to factors such as the growing awareness of chronic pain, supported by governmental initiatives aimed at improving access to treatment and the escalating burden of chronic pain. The Malaysia Chronic Pain Therapeutics Market encompasses various players across different segments, including Pfizer, AstraZeneca, Sanofi, Merck, Roche, AbbVie, Novartis, Duopharma, Pharmaniaga, Healthex, etc., among various others.

CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Dr. Netal Patel

Buy Now

Malaysia Chronic Pain Therapeutics Market Analysis Executive Summary

The Malaysia Chronic Pain Therapeutics Market is anticipated to experience a growth from $119 Mn in 2022 to $192 Mn by 2030, with a CAGR of 6.1% during the forecast period of 2022-2030.

Chronic pain is persistent discomfort lasting beyond the normal recovery from injury or illness. It can result from conditions like arthritis, nerve damage, or fibromyalgia, significantly impacting daily life. Treatment involves a multidisciplinary approach, including medications like analgesics and antidepressants, physical therapy, and exercise to enhance mobility and reduce pain. Cognitive-behavioral therapy addresses the emotional aspects of pain. Interventional procedures such as nerve blocks and acupuncture offer relief. Lifestyle adjustments like stress management and a balanced diet play a crucial role. Personalized treatment plans tailored to individual needs, considering the specific condition and overall health, are key to effectively managing chronic pain and improving quality of life.

Chronic pain is found to be prevalent among senior citizens in Malaysia at 15.2%, with the old age group having the highest incidence. Females, those living in rural regions, and those without a formal education are more likely to have chronic pain according to the most recent estimations.

Malaysia is witnessing market growth due to factors such as the growing awareness of chronic pain, supported by governmental initiatives aimed at improving access to treatment and the escalating burden of chronic pain.

The market has a diverse range of players, including global pharmaceutical corporations, local pharmaceutical businesses, medical device companies, pain clinics, and hospitals. Multinational pharmaceutical corporations such as Pfizer, AbbVie, and Merck are strong competitors for top positions due to their market dominance, brand awareness, and diversified product portfolios. Some local firms such as Duopharma and Pharmaniaga are also some of the key participants that have a strong emphasis on the local market and possible cost savings.

Malaysia Chronic Pain Therapeutics Market Report 2022 to 2030

Market Dynamics

Market Growth Drivers

Increasing awareness: As awareness about the causes and treatment options for chronic pain is growing, there is an increasing demand for effective pain management solutions. This recognition of chronic pain as a significant health problem is pressuring a cultural shift towards acknowledging and addressing this issue and thereby empowering individuals to actively pursue interventions to alleviate their pain.

Government initiatives: This includes a strategic increase in the healthcare budget for funding pain clinics, thereby supporting the healthcare infrastructure dedicated to addressing chronic pain. Additionally, governmental efforts are focused on raising awareness about chronic pain, fostering informed decision-making among the public, and reducing the stigma associated with seeking pain management.

Rising burden of chronic pain: The burden is attributed to various contributing factors. The aging population, escalating rates of obesity, and the ongoing urbanization processes are among the key drivers boosting the prevalence of chronic pain in the country. The convergence of these factors is leading to an increased demand for comprehensive pain management solutions to cater to the diverse needs of individuals grappling with chronic pain conditions.

Market Restraints

Expensive treatment: The expense associated with chronic pain treatment poses a significant challenge, particularly in the context of emerging and advanced therapeutic approaches that often come with higher costs. This economic aspect creates disparities in healthcare accessibility, making it challenging for individuals, regardless of their socioeconomic background, to afford the required treatments for chronic pain.

Limited availability of pain specialists: There is a shortage of pain management experts in Malaysia, which restricts access to specialized care for patients with chronic pain. This scarcity of expertise makes it challenging to provide timely and appropriate diagnosis and treatment tailored to each patient's unique needs.

Misconceptions and stigma surrounding chronic pain: Despite advancements in medical understanding, societal stigma and judgmental attitudes towards chronic pain persist in Malaysia. This stigma can have significant psychological effects, leading patients to delay or avoid seeking medical help. It also hinders the creation of a supportive and empathetic environment for those living with chronic pain.

Healthcare Policies and Regulatory Landscape

The safety, effectiveness, and quality of pharmaceutical goods that are sold in Malaysia are significantly enhanced by the work of the nation's drug regulating agencies. The Ministry of Health (MOH), the Drug Control Authority (DCA), and the National Pharmaceutical regulating Agency (NPRA) are the primary regulating bodies. The MOH is the highest-ranking government agency in charge of the country's healthcare system and public health. The NPRA is in charge of managing standards for testing pharmaceutical goods and putting quality control processes into action. Specifically, the DCA is in charge of registering pharmaceutical goods, assessing their efficacy and safety, and granting permits for the import, export, and production of pharmaceuticals. Together, these regulatory agencies monitor every stage of the medication lifecycle, from development to commercialization and beyond. They create and implement rules, carry out clinical research, keep an eye on adverse drug responses, and guarantee the veracity of public drug information.

Competitive Landscape

Key Players:

  • Pfizer
  • AstraZeneca
  • Sanofi
  • Merck
  • Roche
  • AbbVie
  • Novartis
  • Duopharma
  • Pharmaniaga
  • Healthex

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Malaysia Chronic Pain Therapeutics Market Segmentation

By Indication

  • Neuropathic Pain
  • Back Pain
  • Headaches
  • Arthritis Pain
  • Muscular Pain
  • Idiopathic Pain
  • Others

By Drug Class

  • Analgesics
  • Opioids
  • NSAIDs
  • Anaesthetics
  • Others

By Route of Administration

  • Oral
  • Topical
  • Parenteral
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By End User

  • Hospitals
  • Speciality Clinics
  • Homecare
  • Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 29 May 2024
Updated by: Riya Doshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up